c-Met/HGFR inhibitor kit 包含细胞间质上皮转换因子/细胞生长因子受体c-Met/HGFR 抑制剂,c-Met/HGFR 涉及胚胎发育、器官再生、组织损伤修复等生理过程。细胞生长因子HGF 是已知的c-Met 配体。在多种肿瘤细胞中,由于c-Met 和HGFR 的过表达,c-Met 和HGFR 形成自分泌和旁分泌正反馈回路,造成c-Met/HGFR 信号通路异常活化,促进了肿瘤细胞的发生和发展。TargetMol 为您提供47种精选c-Met/HGFR 抑制剂。所有化合物现货供应,到货快捷,是您预实验探索的不二选择。
ID | Compound | CAS | MW | Concentration | Target |
---|---|---|---|---|---|
T2054 | Altiratinib | 1345847-93-9 | 510.46 | 10mM | c-Met/HGFR; FLT; Tie-2; Trk receptor; VEGFR |
T3209 | AMG-337 | 1173699-31-4 | 463.46 | 10mM | c-Met/HGFR |
T2516 | Amuvatinib | 850879-09-3 | 447.51 | 10mM | Apoptosis; c-Kit; c-Met/HGFR; c-RET; DNA/RNA Synthesis; FLT; PDGFR |
T7900 | BAY-474 | 1033767-86-0 | 289.33 | 10mM | c-Met/HGFR |
T8326 | BMS-2 | 888719-03-7 | 458.42 | 10mM | c-Met/HGFR; FLT; VEGFR |
T2349 | BMS-754807 | 1001350-96-4 | 461.49 | 10mM | c-Met/HGFR; IGF-1R; Trk receptor |
T2699 | BMS 777607 | 1025720-94-8 | 512.89 | 10mM | c-Met/HGFR; TAM Receptor |
T2419 | BMS-794833 | 1174046-72-0 | 468.84 | 10mM | c-Met/HGFR; VEGFR |
T7787 | BMS817378 | 1174161-69-3 | 578.8 | 10mM | c-Met/HGFR |
T10585 | Bozitinib | 1440964-89-5 | 424.38 | 10mM | c-Met/HGFR |
T5164 | Cabozantinib hydrochloride | 1817759-42-4 | 537.96 | 10mM | c-Kit; c-Met/HGFR; FLT; ROR; TAM Receptor; VEGFR |
T4260 | Capmatinib 2HCl | 1197376-85-4 | 485.34 | 10mM | c-Met/HGFR |
T4426 | CEP-40783 | 1437321-24-8 | 588.56 | 10mM | c-Met/HGFR; TAM Receptor |
T10655 | c-Met inhibitor 1 | 1357072-61-7 | 362.41 | 10mM | c-Met/HGFR |
T1661 | Crizotinib | 877399-52-5 | 450.34 | 10mM | ALK; Autophagy; c-Met/HGFR; ROS; ROS Kinase |
T13194 | CSF1R-IN-2 | 2271119-26-5 | 409.42 | 10mM | c-Fms; c-Met/HGFR; Src |
T4332 | c-Kit-IN-1 | 1225278-16-9 | 489.47 | 10mM | c-Kit; c-Met/HGFR |
T11162 | EGFR-IN-8 | 2407957-87-1 | 662.02 | 10mM | EGFR;c-Met/HGFR |
T22324 | Ensartinib hydrochloride | 2137030-98-7 | 634.36 | 10mM | ALK; c-Met/HGFR; Trk receptor |
T3113 | Foretinib | 849217-64-7 | 632.65 | 10mM | c-Met/HGFR; Tie-2; VEGFR |
T5414 | Glumetinib | 1642581-63-2 | 459.48 | 10mM | c-Met/HGFR |
T6517 | Golvatinib | 928037-13-2 | 633.69 | 10mM | c-Met/HGFR; VEGFR |
T25492 | Hepln-13 | 64369-13-7 | 325.2 | 10mM | c-Met/HGFR |
T1963 | Capmatinib | 1029712-80-8 | 412.42 | 10mM | Apoptosis; c-Met/HGFR |
T6095 | JNJ-38877605 | 943540-75-8 | 377.35 | 10mM | c-Met/HGFR |
T15617 | JNJ-38877618 | 943540-74-7 | 374.35 | 10mM | c-Met/HGFR |
T9052 | XL092 | 2367004-54-2 | 528.53 | 10mM | c-Met/HGFR; TAM Receptor; VEGFR |
T3455 | Merestinib | 1206799-15-6 | 552.54 | 10mM | c-Met/HGFR; Discoidin Domain Receptor (DDR); FLT; ROS; ROS Kinase |
T6351 | MGCD-265 analog | 875337-44-3 | 517.6 | 10mM | Apoptosis; c-Met/HGFR; VEGFR |
TQ0219 | MK-8033 | 1001917-37-8 | 471.53 | 10mM | c-Met/HGFR |
TQ0021 | Ningetinib | 1394820-69-9 | 556.58 | 10mM | c-Met/HGFR; TAM Receptor; VEGFR |
T2894 | Norcantharidin | 5442-12-6 | 168.15 | 10mM | c-Met/HGFR; EGFR |
T6907 | NPS-1034 | 1221713-92-3 | 551.54 | 10mM | Apoptosis; c-Met/HGFR; TAM Receptor |
T2680 | NVP-BVU972 | 1185763-69-2 | 340.38 | 10mM | c-Met/HGFR |
T2676 | PF-04217903 | 956905-27-4 | 372.38 | 10mM | c-Met/HGFR |
T6128 | PHA-665752 | 477575-56-7 | 641.61 | 10mM | Apoptosis; Autophagy; Bcr-Abl; c-Met/HGFR; FGFR; VEGFR |
T3274 | S49076 | 1265965-22-7 | 438.13 | 10mM | c-Met/HGFR; FGFR; TAM Receptor |
T5467 | SAR125844 | 1116743-46-4 | 550.63 | 10mM | Apoptosis; c-Met/HGFR |
T5677 | SAR125884 hydrochlorid (1116743-46-4(free base)) | T5677 | 587 | 10mM | c-Met/HGFR |
TQ0210 | Savolitinib | 1313725-88-0 | 345.36 | 10mM | c-Met/HGFR |
T5349 | SCR-1481B1 | 1174161-86-4 | 742.07 | 10mM | c-Met/HGFR; VEGFR |
T2293 | SGX-523 | 1022150-57-7 | 359.41 | 10mM | Bcr-Abl; c-Met/HGFR; p38 MAPK; Raf |
T5478 | SRI 31215 TFA | 1832686-44-8 | 533.6 | 10mM | c-Met/HGFR |
T6154 | SU11274 | 658084-23-2 | 568.09 | 10mM | Apoptosis; Autophagy; c-Met/HGFR; CDK; FGFR; VEGFR |
T13108 | Pamufetinib | 1190836-34-0 | 518.56 | 10mM | c-Met/HGFR; VEGFR |
T6121 | Tepotinib | 1100598-32-0 | 492.57 | 10mM | c-Met/HGFR; TAM Receptor; Trk receptor |
T6117 | Tivantinib | 905854-02-6 | 369.42 | 10mM | Apoptosis; c-Met/HGFR |